165 related articles for article (PubMed ID: 38758556)
21. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
Wen H; Hockenberry JM; Borders TF; Druss BG
Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
[TBL] [Abstract][Full Text] [Related]
22. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine.
Andrilla CHA; Jones KC; Patterson DG
J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
[TBL] [Abstract][Full Text] [Related]
24. Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency.
Paiva TJ; Wightman RS; St John K; Nitenson AZ; Onyejekwe C; Hallowell BD
J Subst Use Addict Treat; 2024 Jul; 162():209382. PubMed ID: 38677597
[TBL] [Abstract][Full Text] [Related]
25. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings.
Gordon AJ; Kenny M; Dungan M; Gustavson AM; Kelley AT; Jones AL; Hawkins E; Frank JW; Danner A; Liberto J; Hagedorn H
Am J Addict; 2022 Mar; 31(2):152-158. PubMed ID: 35118756
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients.
Abraham R; Wilkinson E; Jabbarpour Y; Petterson S; Bazemore A
J Am Board Fam Med; 2020; 33(1):9-16. PubMed ID: 31907241
[TBL] [Abstract][Full Text] [Related]
27. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.
Andrilla CHA; Coulthard C; Larson EH
Ann Fam Med; 2017 Jul; 15(4):359-362. PubMed ID: 28694273
[TBL] [Abstract][Full Text] [Related]
28. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
29. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
[TBL] [Abstract][Full Text] [Related]
31. Role of the National Health Service Corps in Delivering Substance Use Disorder Treatment in Underserved Communities.
Rowan K; Knudson A; Anderson B; Satorius J; Shah S; Stahl A; Kepley H
Psychiatr Serv; 2023 Jun; 74(6):636-643. PubMed ID: 36751906
[TBL] [Abstract][Full Text] [Related]
32. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines.
Jones CM; Olsen Y; Ali MM; Sherry TB; Mcaninch J; Creedon T; Juliana P; Jacobus-Kantor L; Baillieu R; Diallo MM; Thomas A; Gandotra N; Sokolowska M; Ling S; Compton W
JAMA Health Forum; 2023 Jul; 4(7):e231982. PubMed ID: 37477926
[TBL] [Abstract][Full Text] [Related]
34. Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine.
Hawk KF; D'Onofrio G; Chawarski MC; O'Connor PG; Cowan E; Lyons MS; Richardson L; Rothman RE; Whiteside LK; Owens PH; Martel SH; Coupet E; Pantalon M; Curry L; Fiellin DA; Edelman EJ
JAMA Netw Open; 2020 May; 3(5):e204561. PubMed ID: 32391893
[TBL] [Abstract][Full Text] [Related]
35. Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis.
Roy PJ; Suda K; Luo J; Lee M; Anderton J; Olejniczak D; Liebschutz JM
Int J Drug Policy; 2024 Apr; 126():104381. PubMed ID: 38457960
[TBL] [Abstract][Full Text] [Related]
36. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.
Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R
JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034
[TBL] [Abstract][Full Text] [Related]
37. Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder.
Jones J; Tierney M; Jacobs G; Chien SY; Mallisham S
J Addict Nurs; 2020; 31(4):261-268. PubMed ID: 33264198
[TBL] [Abstract][Full Text] [Related]
38. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
39. Practice Predictors of Buprenorphine Prescribing by Family Physicians.
Peterson LE; Morgan ZJ; Borders TF
J Am Board Fam Med; 2020; 33(1):118-123. PubMed ID: 31907252
[TBL] [Abstract][Full Text] [Related]
40. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
